Franco Marina Santiago, Gomes Eliza Rocha, Roque Marjorie Coimbra, Oliveira Mônica Cristina
Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Front Oncol. 2021 Mar 16;11:623760. doi: 10.3389/fonc.2021.623760. eCollection 2021.
Since more than 40 years liposomes have being extensively studied for their potential as carriers of anticancer drugs. The basic principle behind their use for cancer treatment consists on the idea that they can take advantage of the leaky vasculature and poor lymphatic drainage present at the tumor tissue, passively accumulating in this region. Aiming to further improve their efficacy, different strategies have been employed such as PEGlation, which enables longer circulation times, or the attachment of ligands to liposomal surface for active targeting of cancer cells. A great challenge for drug delivery to cancer treatment now, is the possibility to trigger release from nanosystems at the tumor site, providing efficacious levels of drug in the tumor. Different strategies have been proposed to exploit the outer and inner tumor environment for triggering drug release from liposomes and are the focus of this review.
四十多年来,脂质体因其作为抗癌药物载体的潜力而受到广泛研究。其用于癌症治疗的基本原理基于这样一种理念,即它们可以利用肿瘤组织中存在的血管渗漏和淋巴引流不畅的情况,被动地在该区域蓄积。为了进一步提高其疗效,人们采用了不同的策略,如聚乙二醇化,这能使脂质体循环时间更长,或在脂质体表面连接配体以实现对癌细胞的主动靶向。如今,药物递送用于癌症治疗面临的一个巨大挑战是能否在肿瘤部位触发纳米系统释放药物,从而在肿瘤中提供有效的药物水平。人们已经提出了不同的策略来利用肿瘤的外部和内部环境触发脂质体释放药物,这也是本综述的重点。